Hoechst Pakistan Limited (HPL): FY24 Corporate Briefing Takeaways - By Taurus Research
Apr 8 2025
Taurus Securities
- HPL, formerly known as Sanofi-Aventis Pakistan Limited, has experienced a remarkable transformation since its acquisition by Packages Group. The Company has seen significant growth, reflected in its recent financial performance, including its highest-ever PAT. In FY24, HPL reported a revenue of ~PKR 26Bn, marking a 25%YoY increase from PKR 21Bn in FY23.
- The Company's margins improved by 6ppts, reaching 32%, driven by a favorable sales mix and a robust product portfolio. Notably, HPL achieved a PAT of ~PKR 1.8Bn, up 4.2xYoY from PKR 361Mn in the previous year. This impressive growth can be attributed to higher sales, enhanced gross margins, effective cost optimization, and a strategic pricing approach.
- HPL's sales mix is composed of 30% non-essential drugs and 70% essential medications. The revenue stream is generated from 54% imported medicines, primarily essential drugs, and 46% locally produced products. The Company’s portfolio features well-known medications, including Flagyl, Clexane, Haemaccel, and Selsun Blue.
Current:
Open:
Volume:
Change: ()
High:
Low:
52 Week High:
Vol Avg(12 m):
Free Float:
52 Week Low:
Market Cap:
Total Share:
Relative Strength Index (RSI)
RSI:
MACD Signals
MACD DAILY:
MACD WEEKLY:
Simple Moving Avg (SMA)
SMA(10):
SMA(30):
SMA(60):
SMA(200):
Performance
One Month:
Three Months:
Six Months:
Twelve Months:
Support & Resistance
Support 1:
Resistance 1:
Support 2:
Resistance 2:
High & Lows
Period
High
Low